1217237-98-3Relevant academic research and scientific papers
NOVEL COMPOUNDS HAVING ESTROGEN RECEPTOR ALPHA DEGRADATION ACTIVITY AND USES THEREOF
-
Paragraph 0575; 0579, (2020/06/08)
The present disclosure relates to novel compounds having estrogen receptor alpha degradation activity, pharmaceutical compositions containing such compounds, and their use in prevention and treatment of cancer and related diseases and conditions.
TETRASUBSTITUTED ALKENE COMPOUNDS AND THEIR USE
-
Page/Page column 54; 55, (2016/12/22)
Disclosed herein are compounds, or pharmaceutically acceptable salts thereof, and methods of using the compounds for treating breast cancer by administration to a subject in need thereof a therapeutically effective amount of the compounds or pharmaceutically acceptable salts thereof. The breast cancer may be an ER-positive breast cancer and/or the subject in need of treatment may express a mutant ER-α protein.
A new Suzuki synthesis of triphenylethylenes that inhibit aromatase and bind to estrogen receptors α and β
Zhao, Li-Ming,Jin, Hai-Shan,Liu, Jinzhong,Skaar, Todd C.,Ipe, Joseph,Lv, Wei,Flockhart, David A.,Cushman, Mark
, p. 5400 - 5409 (2016/10/24)
The design and synthesis of dual aromatase inhibitors/selective estrogen receptor modulators (AI/SERMs) is an attractive strategy for the discovery of new breast cancer therapeutic agents. Previous efforts led to the preparation of norendoxifen (4) deriva
